Diagnostic Value of Serum CA125 and Human Epidiymis Protein 4 for Epithelial Ovarian Cancer and Its Relationship with Clinical Pathological Characteristics and Prognosis
DENG Meixian, et al
The Fifth Hospital of Wuhan, Hubei Wuhan 430050, China
Abstract：Objective: To analyze the diagnostic value of serum carbohydrate antigen 125 (CA125) and human epidiymis protein 4 (HE4) for epithelial ovarian cancer and its relationship with clinical pathological characteristics and prognosis. Methods: The clinical data of 96 patients with epithelial ovarian cancer (malignant group) and 90 patients with benign ovarian disease (benign group) admitted in our hospital from April 2014 to April 2019 were retrospectively analyzed. Serum HE4 and CA125 levels were compared,and the results of pathological diagnosis were used as the gold standard to compare the sensitivity,specificity and accuracy of serum HE4 and CA125 levels in the diagnosis of epithelial ovarian cancer and benign ovarian disease. The clinicopathological characteristics and short-term prognosis of all patients with epithelial ovarian cancer were recorded. The expressions of serum HE4 and CA125 in patients with different pathological features were compared,and logistic regression model was used to analyze the independent risk factors affecting the prognosis of patients with epithelial ovarian cancer. Results: The levels of HE4 and CA125 in the malignant group were higher than those in the benign group (P<0.05). The clinical efficacy of serum HE4 in the diagnosis of epithelial ovarian cancer is higher than that of serum CA125 (P<0.05). The sensitivity and accuracy of the combined diagnosis of serum HE4 and CA125 were 96.88% and 94.09%,respectively,which were higher than those of any single serum detection (P<0.05),and there was no difference in the specificity between the combined diagnosis and single serum HE4 diagnosis (P>0.05).The positive expression rates of serum HE4 and CA125 in patients with FIGO stage Ⅲ + Ⅳ and low differentiation are higher than those in patients with FIGO stage Ⅰ + Ⅱ and medium and high differentiation (P<0.05). The patients who are in FIGO stage Ⅲ + Ⅳ,and have low degree of differentiation,CA125> 500U / ml,positive serum HE4 and lymphatic metastasis have low survival rates (P<0.05). FIGO stage Ⅲ + Ⅳ,lymphatic metastasis,low degree of differentiation,CA125> 500U / mL,and positive HE4 are independent risk factors affecting the prognosis of patients with epithelial ovarian cancer (P<0.05). Conclusion: ① Serum HE4 and CA125 are highly expressed in patients with epithelial ovarian cancer,which can be used as an early screening method in the high population,but the clinical value of combined diagnosis is better than that of single serum detection. ②The expression levels of serum HE4 and CA125 are closely related to the clinicopathological characteristics and prognosis of patients. FIGO stage Ⅲ+Ⅳ,lymphatic metastasis,low degree of differentiation,CA125> 500U / mL,positive HE4 are independent risk factors that affect the prognosis of patients with epithelial ovarian cancer,and can be used as an effective indicator to predict the prognosis of patients.
邓梅先, 刘伟, 柯水香. 血清CA125人附睾蛋白4对卵巢上皮性癌诊断价值及与其临床病理特征及预后的关系研究[J]. 河北医学, 2021, 27(3): 418-424.
DENG Meixian, et al. Diagnostic Value of Serum CA125 and Human Epidiymis Protein 4 for Epithelial Ovarian Cancer and Its Relationship with Clinical Pathological Characteristics and Prognosis. HeBei Med, 2021, 27(3): 418-424.
[1] Dayyani F,Uhlig S,Colson B,et al.Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian Cancer[J].International Journal of Gynecological Cancer,2016,26(9):1586~1593. [2] 冯华萍,赵绍杰,唐艳.左炔诺孕酮缓释系统联合达菲林治疗子宫腺肌症的疗效及对血清CA125 CA199 HE4的影响[J].河北医学,2019,25(1):5~9. [3] Bian J,Sun X X,Li B,et al.[EXPRESS]:Clinical significance of serum HE4,CA125,CA724 and CA19-9 in patients with endometrial cancer[J].Technology in cancer research&treatment,2016,16(4):1781~1785. [4] 和晓利,张菊新,靖爽,等.血清人附睾蛋白4和糖链抗原125诊断卵巢癌的价值[J].中华实用诊断与治疗杂志,2017,31(3):245~247. [5] 张霆,张清华,姚丽艳,等.上皮性卵巢癌患者血清CA125、HE4、CEA水平表达及临床意义[J].解放军医药杂志,2018,30(8):38~41. [6] Chunhua D,Ping L,Chao L.Value of HE4 combined with cancer antigen 125 in the diagnosis of endometrial cancer[J].Pakistan Journal of Medical Sciences,2017,33(4):754~758. [7] 崔彭华,张玉娟,邵雪斋,等.子宫内膜癌组织LSD1、HE4、CA125及CA19-9变化及临床意义[J].临床误诊误治,2019,32(1):19~22. [8] 杨潇,王艳清,鲜舒,等.转录因子YY1在妇科肿瘤和妊娠疾病中的作用[J].医学分子生物学杂志,2017,14(4):239~245. [9] 刘秀玲,贺全勤.血清HE4、CA125、SCC-Ag联合检测对诊断子宫内膜癌的临床价值%[J].实用癌症杂志,2019,34(4):675~677. [10] 徐宝琳. 血清AFP、HE4、CA125、SMRP与卵巢癌病理参数的相关性研究[J].中国妇幼保健,2017,32(14):3162~3164. [11] 徐曦,李艳,袁远霞,等.MRI检查联合血清CA125、人附睾蛋白4水平检测对卵巢癌诊断效能分析[J].中国CT和MRI杂志,2020,18(7):118~120.
2021, Vol. 27 
冀公网安备13080202000677号